Tilray Brands, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tilray Brands, Inc. on March 3, 2022. The filing discloses two significant corporate events: the entry into an "at-the-market" equity sales agreement and the execution of term sheets to acquire and amend debt securities issued by Hexo Corp.
Key Financial Metrics and Agreements
- Equity Offering: Entered into a Sales Agreement to offer and sell Class 2 Common Stock with an aggregate offering price of up to $400,000,000.
- Transaction Costs: Sales agents (Jefferies LLC and Canaccord Genuity LLC) are entitled to a commission of up to 3.0% of gross proceeds.
- Debt Acquisition: Entered a term sheet to acquire Hexo Corp. secured convertible notes with an outstanding principal balance of approximately $211 million.
- Purchase Price: The acquisition price is set at 95% of the outstanding principal balance plus accrued and unpaid interest.
- Payment Terms: Consideration may be paid in cash, Class 2 Common Stock, or a combination thereof.
Material Changes and Strategic Actions
The filing details a strategic shift involving Hexo Corp. debt:
- Note Amendment: Upon acquisition, the maturity date of the Hexo notes will be extended by three years to May 1, 2026.
- Conversion Price: The initial conversion price of the notes will be adjusted to Canadian $0.90.
- Governance Rights: Tilray will receive the right to appoint one director and one board observer to Hexo's board.
- Protective Rights: Tilray is granted "top-up" and preemptive rights to maintain its percentage ownership in Hexo on an "as-converted" basis.
- Operational Synergies: The parties agreed to work in good faith to evaluate production efficiencies and cost-saving synergies.
Outlook, Risks, and Contingencies
The transactions regarding the Hexo notes are subject to several contingencies, including the negotiation and execution of definitive agreements, satisfactory completion of financial due diligence, receipt of stock exchange approval by Hexo, board approvals, and Hexo shareholder approval. The equity sales agreement allows Tilray to suspend offers or terminate the agreement at any time. No sales of the Common Stock under the Sales Agreement will be made in Canada or to Canadian residents.
Key Facts for Investor Verification
- Verify the final execution of definitive agreements for the Hexo note acquisition and amendment.
- Monitor the actual volume of shares sold under the $400 million "at-the-market" program and the resulting dilution.
- Confirm the mix of cash versus stock used to pay for the Hexo notes.
- Track the progress of Hexo shareholder and board approvals required to close the debt transaction.
- Assess the impact of the 3.0% commission on net proceeds from any equity sales.